Table 2 Results of a priori outcome prediction on the independent test set.
Features | Accuracy (%) | Sensitivity (%) | Specificity (%) | AUC |
|---|---|---|---|---|
Radiomic Features: Elongation-Tumour, T1-GLDM-GLN-Edema, T2-GLDM-HGLE-Tumour, T1-GLSZM-LAHGLE-Edema | 87 | 85 | 88 | 0.87 |
Clinical Features: Previous WBRT, Targeted Systemic Treatment, TD, Histology | 63 | 62 | 65 | 0.62 |
Radiomic Features + Previous WBRT | 77 | 69 | 82 | 0.76 |
Radiomic Features + (Previous WBRT, Targeted Systemic Treatment) | 67 | 54 | 76 | 0.65 |
Radiomic Features + (Previous WBRT, Targeted Systemic Treatment, TD) | 70 | 62 | 76 | 0.69 |
Radiomic Features + (Previous WBRT, Targeted Systemic Treatment, TD, Histology) | 67 | 54 | 76 | 0.65 |
Clinical Features + Elongation-Tumour | 70 | 69 | 71 | 0.70 |
Clinical Features + (Elongation-Tumour, T1-GLDM-GLN-Edema) | 73 | 62 | 83 | 0.72 |
Clinical Features + (Elongation-Tumour T1-GLDM-GLN-Edema, T2-GLDM-HGLE-Tumour) | 67 | 54 | 76 | 0.65 |
Clinical Features + (Elongation-Tumour, T1-GLDM-GLN-Edema, T2-GLDM-HGLE-Tumour, T1-GLSZM-LAHGLE-Edema) | 67 | 54 | 76 | 0.65 |
